
    
      Besides the main objective, there are 3 other objectives as follows:

        1. To determine dose-limiting toxicity (DLT) of HM781-36B

        2. To characterize the pharmacokinetics of HM781-36B, following oral administration of
           HM781-36B

        3. To evaluate anticancer activity of HM781-36B in patients with advanced solid
           malignancies Groups of 3 patients per cohort or dose level will be treated with
           escalating doses of HM781-36B
    
  